Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24913779 | 0.92 | KDM4E (0.51) | KDM4EHCAR3MAPK1MAPTPKM | |
| SCHEMBL30980960 | 0.92 | KDM4E (0.51) | KDM4EHCAR3MAPK1MAPTPKM | |
| SCHEMBL24913769 | 0.92 | KDM4E (0.51) | KDM4EHCAR3MAPK1MAPTPKM | |
| SCHEMBL23177148 | 0.92 | KDM4E (0.51) | KDM4EHCAR3MAPK1MAPTPKM | |
| SCHEMBL30980968 | 0.92 | KDM4E (0.51) | KDM4EHCAR3MAPK1MAPTPKM | |
| SCHEMBL1519355 | 0.90 | MAPT (0.54) | KDM4EHCAR3MAPK1MAPTPKM | |
| SCHEMBL17678246 | 0.87 | HCAR3 (0.64) | HCAR3MAPK1MAPTPKMRAB9A | |
| SCHEMBL2253578 | 0.86 | KDM4E (0.52) | KDM4EHCAR3MAPK1MAPTPKM | |
| SCHEMBL1595672 | 0.85 | MAPT (0.65) | HCAR3MAPK1MAPTPKMRAB9A | |
| SCHEMBL23152110 | 0.85 | HCAR3 (0.53) | KDM4EHCAR3MAPK1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497392-B2 | EP300/CBP inhibitor | HINOVA PHARMACEUTICALS INC. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20230027088-A1 | EP300/CBP INHIBITOR | HINOVA PHARMACEUTICALS INC. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230027088-A1 | EP300/CBP INHIBITOR | HINOVA PHARMACEUTICALS INC. (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-4043458-A1 | EP300/CBP INHIBITOR | Hinova Pharmaceuticals Inc. (CN) | 2022-08-17 | — | — | EP | disclosed |
| CN-113166139-A | Pyrrolo [2,3-b ] pyridines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2021057915-A1 | EP300/CBP INHIBITOR | 成都海创药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-10118920-B2 | Isoxazolyl substituted benzimidazoles | CELLCENTRIC LTD (GB) | 2018-11-06 | — | — | US | disclosed |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| EP-3286183-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | Cellcentric Ltd (GB) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016170324-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016170324-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497392-B2 | EP300/CBP inhibitor | EP300, MLLT1, CREBBP | KDM4E 143/4885HCAR3 2697/4885MAPK1 435/4885 |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | EP300, HDAC3, HDAC1 | KDM4E 478/4885HCAR3 808/4885MAPK1 2150/4885 |
| US-20230027088-A1 | EP300/CBP INHIBITOR | EP300, MLLT1, CREBBP | KDM4E 143/4885HCAR3 2697/4885MAPK1 435/4885 |
| US-10118920-B2 | Isoxazolyl substituted benzimidazoles | EP300, HDAC3, HDAC1 | KDM4E 478/4885HCAR3 808/4885MAPK1 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.